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nurses who train on-the-job. Most countries do not have 
focused education programmes for RTTs. 
 
Conclusions: The results indicate heterogeneity with regards 
to appropriate levels of infrastructure. Some countries reach 
(Turkmenistan) or approach (Azerbaijan, Russia, Belarus and 
Ukraine) 1 TT machine/1000 cancer patients/year relative to 
2012 cancer statistics. 
These indicators represent an approximate estimate of 
resource availability, but do not reflect patient access or 
quality of the radiotherapy services. 
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Radiotherapy (RT) has always been kept, one way or  
another, as a part of the multidisciplinary management of 
small-cell lung cancer (SCLC). In 1957, a clear distinction 
between two categories of SCLC – limited-disease (LD) and 
extensive-disease (ED) – depending on the possibility of 
inclusion of all possible disease sites into a single radiation 
portal – was made. This reflects a historically recognized 
value of RT for treatment outcome of SCLC. Nowadays, in the 
era of the use of modern technologies for imaging and RT 
planning, the distinction between LD and ED is made on the 
basis of the presence of distant metastases. But still we 
weigh up a value and the extent of improvement of outcome 
with RT use separately for LD and ED.   
Thoracic RT in combination with chemotherapy and 
prophylactic cranial irradiation (PCI) increase 3-year survival 
by approximately 5% each, as shown in the meta-analyses. 
One randomized phase III trial demonstrated also a survival 
advantage by PCI of 13.5% at one year for ED-SCLC. Recently, 
it was demonstrated in a randomized trial that the addition 
of thoracic RT (30 Gy in ten fractions) after any response to 
chemotherapy in ED-SCLC improved 2-year survival.  Although 
all of these improvements per se are relatively small there is 
a wide consensus among oncologists that these treatments 
should be offered to SCLC patients.  Additionally, these 
advancements in the therapy of SCLC are worth of 
consideration in the context of poor survival unchanged with 
the use of chemotherapy over the past thirty years.  
What next? Could we improve survival further with 
radiotherapy?  
Certainly, it is a room for improvement in some areas which 
are still under investigation as an issue of radiotherapy dose, 
timing, fractionation and target volumes. Current 
recommendation for LD-SCLC is the use of radio-
chemotherapy with early accelerated hyper-fractionated RT. 
However, such an approach may not be convenient and its 
toxicity makes it unfeasible for fragile and/or elderly 
patients. The use of newer RT technologies and proper 
selection of patients for aggressive radio-chemotherapy 
schedules are expected to improve treatment tolerance. 
A small improvement of survival obtained with PCI may be 
compromised by worse quality-adjusted life expectancy in 
long term survivors, as the pronounced effect of 
neurotoxicity (NT) becomes apparent after several years. 
What factors should be considered for an individual patient 
to find a balance between benefits of prolongation of survival 
by the reduction in the incidence of brain metastases and the 
risks of short-term and long-term toxicity?  Over the past 
fifteen years, since an influence of PCI on survival was first 
demonstrated, magnetic resonance imaging (MRI) has become 
the imaging technique of choice in patients suspected of 
brain metastases. This change may decrease the number of 
patients eligible for PCI, as MRI is more sensitive than 
computerized tomography in detecting brain metastases. For 
better understanding of the extent and severity of late NT, 
long-term follow-up of patients included in prospective 
studies is needed. Also, some attempts have been made to 
prevent the development of neurocognitive decline 
attributed to brain irradiation. Long-term outcome of such 
approach is awaited.  
Thoracic RT and PCI obviously do not decrease the 
progression rate outside the thorax and brain, thus the 
addition of RT to sites of extrathoracic and extracerebral 
metastases might also merit investigation. It is in line with 
growing interest and increasing data that accumulate 
evidence on the value of RT in the treatment of 
oligometastatic disease for other cancers. Such an approach 
is being investigated in the randomized trial by the Radiation 
Therapy Oncology Group.   
Advancements in RT technologies proved to increase survival 
rates in population-based studies for Non-SCLC patients. It is 
reasonable to expect that it is also valid for SCLC patients; 
better radiation volume definition prevents from 
geographical misses and reduces unnecessary healthy tissues 
irradiation.  
All these issues will be discussed in detail during the lecture.  
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Much has been said already on the complexities and 
unknowns in management of cancer in the elderly, by 
2020 more than 50% of all newly diagnosed patients with 
cancer older than 65 years, >30% when >75 years and about 
10% over 85 years in most European countries. Above age 65 
and rising with age, about 10% of newly diagnosed cancers is 
a second cancer, excluding those in the same organ site [skin 
- basal cell carcinoma (BCC) and large bowel as well as 
